Further validation of such assays and honing them to be performed in the clinical setting using limited numbers of cells from tumor samples will improve our ability to match patients to the most effective pro-apoptotic therapies like ABT-199 and will further pave the way for using small molecule Bcl-2 antagonists in the clinic for those pediatric NB patients most likely to respond. The gene discussed is BCL2; the disease is neuroblastoma.